NEW YORK (GenomeWeb) ― Manipulating miniature droplets and subjecting them to high temperatures on an open digital microfluidic device leads to evaporation that can seriously disrupt concentration-dependent enzymatic reactions, like PCR.
NEW YORK (GenomeWeb) — Seattle-based start-up Lamprogen, a spinout of the University of Washington, is using funding from two grants to further the development of a self-digitizing microfluidic chip and instrument on which the chip will run.
NEW YORK (GenomeWeb) — Virologists at the University of Washington and the Fred Hutchinson Cancer Research Center recently reported that in a small, retrospective study droplet digital PCR appeared to have no added benefit over qPCR for clinical monitoring of human cytomegalovirus load in transpl
NEW YORK (GenomeWeb) — Researchers from Virginia Commonwealth University have developed a method of quantifying multiple nucleic acid targets in a single sample by combining low-cycle-number, target-specific PCR with atomic force microscopy.
NEW YORK (GenomeWeb) — RUCDR Infinite Biologics, the research services and biorepository arm of the Rutgers University Cell and DNA Repository (RUCDR), has been named a RainDance Technologies Center of Excellence, the partners said this week.
NEW YORK (GenomeWeb) — RUCDR Infinite Biologics, the research services and biorepository arm of the Rutgers University Cell and DNA Repository (RUCDR), has been named a RainDance Technologies Center of Excellence, the partners said today.
NEW YORK (GenomeWeb) — Bay Area startup Toma Biosciences emerged from stealth mode this month with a new cancer assay designed to provide physicians with information to help them personalize and optimize treatments for cancer patients.
Bio-Rad Laboratories this week announced an expansion of its PrimePCR probe assays for Droplet Digital PCR, adding 56 assays for mutation detection and 109 assays for copy number variation analysis to the company's existing catalog for the QX100 and QX200 Droplet Digital PCR systems.
Researchers from several European institutions have used a clinical trial of children with stage IV neuroblastoma to test prospectively whether varying levels of several mRNA markers could stratify patients according to their outcomes.